p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
复制标题
DOI：
10.1002/path.1166
复制
发表时间：
2002-09-01
影响因子：
7.3
通讯作者：
Viale, G
中科院分区：
文献类型：
--
作者：
Pelosi, G;Pasini, F;Viale, G
The p63 protein, a member of the p53 family of nuclear transcription factors, is characterized by different capabilities of transactivating reporter genes, inducing apoptosis, and functioning as dominant-negative agent. This study evaluated the prevalence and prognostic implications of p63 immunoreactivity in 221 patients with stage I non-small cell lung carcinoma (NSCLC) and in 57 patients with stage I-IV neuroendocrine tumours (NET). The results were correlated with the tumour proliferative fraction, the accumulation of p53 protein, and with patient survival. p63 immunoreactivity was seen in 109/118 squamous cell carcinomas, 15195 adenocarcinomas, 2/2 adenosquamous carcinomas, 4/6 large cell carcinomas, 9/20 poorly differentiated NET, and 1/37 typical and atypical carcinoids (p
